Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
Get Acquainted with Imugene’s Deep Product Pipeline

Get Acquainted with Imugene’s Deep Product Pipeline

Summary Backed by an international leadership team with extensive commercialisation expertise in the sector, Imugene has developed a robust product portfolio, comprising four potential drugs. In 2020, Imugene intends to progress with Phase 1 tr...

Read More...
Imugene’s Preclinical New Mimotope Cancer Vaccine Research Published in Prestigious Journal

Imugene’s Preclinical New Mimotope Cancer Vaccine Research Published in Prestigious Journal

Summary Imugene's preclinical research associated with mimotope vaccines targeting immune checkpoint inhibitors published in 'Frontiers in Immunology' journal. Research discovered that mimotope peptides when included in Imugene's exclusive immu...

Read More...
Catch Sight of Imugene’s Clinical Plan for PD1-Vaxx and CF33 Phase 1 Trials

Catch Sight of Imugene’s Clinical Plan for PD1-Vaxx and CF33 Phase 1 Trials

Clinical stage Australian immuno-oncology company, Imugene Limited (ASX:IMU) is set to kickstart two clinical trials with B-cell immunotherapy - PD1-Vaxx and oncolytic virotherapy CF33 this year. Recently, Imugene presented presentations on the clini...

Read More...
Another Notch in Imugene’s Belt, IDMC Confirms Safety of HER-Vaxx Phase 2 Study

Another Notch in Imugene’s Belt, IDMC Confirms Safety of HER-Vaxx Phase 2 Study

The Independent Data Monitoring Committee (IDMC) members have no safety concerns regarding B-cell immunotherapy HER-Vaxx, and biotech player Imugene Limited (ASX:IMU) can continue with its Phase 2 trial without modification, confirmed IDMC chair in a...

Read More...
Take a Quick Peek into Imugene’s Q1 2020 Operational Highlights

Take a Quick Peek into Imugene’s Q1 2020 Operational Highlights

Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) will present the clinical plans for the initial Phase 1 trials of its oncolytic virus, Vaxinia (CF33-hNIS) and its PD-1 targeting cancer immunotherapy, PD1-Vaxx at th...

Read More...
Noteworthy! Imugene Continuing its Planned Activities amid COVID-19 Pandemic

Noteworthy! Imugene Continuing its Planned Activities amid COVID-19 Pandemic

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) is actively implementing risk mitigation and business continuity strategies amidst the global COVID-19 pandemic to continue with its planned activities. The Compa...

Read More...
Cast an Eye Over Imugene’s Impressive Achievements in 1H FY20

Cast an Eye Over Imugene’s Impressive Achievements in 1H FY20

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released another set of robust operational results for the half-year ended 31st December 2019. It was certainly a remarkable half-year for the biotech player,...

Read More...
A Flip Through Imugene’s December 2019 Quarterly 4C Report

A Flip Through Imugene’s December 2019 Quarterly 4C Report

Australia-headquartered clinical stage immuno-oncology player, Imugene Limited (ASX:IMU) has recently released its Quarterly 4C report on the ASX, highlighting its key activities undertaken during December 2019 quarter. Imugene continued to focus on ...

Read More...
Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Australia-headquartered clinical stage immuno-oncology player, Imugene Limited (ASX:IMU) has hit a new milestone, with the completion of GMP manufacturing and preclinical toxicology studies for its B-cell cancer immunotherapy - PD1-Vaxx. These pre-c...

Read More...
A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

It’s surely a prosperous new year for the clinical-stage immuno-oncology player, Imugene Limited (ASX:IMU) that has received core US patent in the largest pharmaceutical market of the world. The United States Patent and Trademark Office (USPTO...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK